L.M. Saptarova1, E.A. Imelbaeva2, G.A. Bayburina3, A.V. Tukhbatova4, G.F. Shakirova5, Sh.N. Galimov6

1–4, 6 FSBEO HE Bashkir State Medical University of the Ministry of Health of Russia (Ufa, Russia)

5 Republican Clinical Oncological Dispensary, Ministry of Health of Bashkir Republic (Ufa, Russia)

1 saptarovaliliana@yandex.ru, 2 imelbaeva@mail.ru, 3 gulnar.2014@mail.ru, 4,5 tuhbatovaav@yandex.ru, 6 sngalim@mail.ru

Myeloperoxidase (MPO) is an iron-containing metabolic enzyme that is an endogenous peroxidase and is encoded by the MPO gene on chromosome 17. Its molecular weight is M 150 kDa, is a cationic heterotetramer consisting of two light non-glycosylated chains of 12 kDa and two heavy glycosylated chains of 57 kDa. These chains are bound to the prosthetic complex of the heme group and calcium ions, forming hetero- and homodimers connected by disulfide bonds.

The metabolic enzyme MPO has an important protective function in the body, expressed in neutrophils and producing hypohalogenated acids that provide antimicrobial activity. In particular, it synthesizes hypochlorous acid (HOCl) from hydrogen peroxide (H2O2) and anion chloride (Cl−). However, in some cases, the activity of this enzyme can lead to damage to the body's own tissues in the foci of inflammation. MPO catalyzed reaction products such as hypochlorite, reac.

MPO is an important indicator of the intensity of inflammatory processes in the body. Its activity is closely related to resistance to infections: a decrease in MPO activity leads to a weakening of protection and contributes to the development of pathological processes.

The role of the MPO enzyme in the development and progression of breast cancer has been established. Active research in this area opens up prospects for the development of new strategies for combating cancer. In particular, the study of myeloperoxidase activity in cancer may lead to the creation of MPO inhibitors. These substances, by blocking the action of the enzyme, are potentially able to slow down tumor growth and prevent metastasis. Further studies will assess the efficacy and safety of MPO inhibitors as a component of comprehensive cancer therapy.

Saptarova L.M., Imelbaeva E.A., Bayburina G.A., Tukhbatova A.V., Shakirova G.F., Galimov Sh.N. The role of myeloperoxidase in breast cancer. Technologies of Living Systems. 2025. V. 22. № 4. Р. 42-48. DOI: https://doi.org/10.18127/j20700997-202504-05
(In Russian).

1. Panasenko O.M., Mihal'chik E.V., Gorudko I.V. Vliyanie antioksidantov i skavendzherov gipogaloidnyh kislot na aktiva-ciyu nejtrofilov lipoproteinami nizkoj plotnosti, modificirovannymi gipohloritom. Biofizika. 2016. T. 61. № 3. S. 500–509. DOI: 10.1134/S0006350916030131 (in Russian).
2. Ahmed A.A.M., Aissa A.A. Rol' okislitel'nogo stressa v muzhskom besplodii u zhitelej Jemena. Tekhnologii zhivyh sistem. 2020. T. 17. № 4. C. 86–89. DOI: 10.18127/j20700997-202004-10 (in Russian).
3. Ruleva N.YU., Zvyaginceva M.A., Dugin S.F. Mieloperoksidaza: biologicheskie funkcii i klinicheskoe znachenie. Sovremen-nye naukoemkie tekhnologii. 2007. № 8. S. 11–14. (in Russian).
4. Valadez-Cosmes P., Raftopoulou S., Mihalic Z.N. et al. Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target. Pharmacology & Therapeutics 2022. V. 236. P. 108052. DOI: 10.1016/j.pharmthera.2021.108052
5. Pahwa R., Modi P., Jialal I. Myeloperoxidase Deficiency. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022.
6. Saptarova L.M., Imel'baeva E.A., Tuhbatova A.V. i dr. Perspektivy ispol'zovaniya mikroRNK. Tekhnologiya zhivyh si-stem. 2025. № 2. S. 49–57. DOI: 10.18127/j20700997-202502-05 (in Russian).
7. Davies M.J., Hawkins C.L. The role of Myeloperoxidase in biomolecule modification, chronic inflammation, and disease. Antioxid. redox signal. 2020. V. 32(13). P. 957–981. DOI: 10.1089/ars.2020.8030
8. Saptarova L.M., Bikmetova E.R., Bajburina D.E. i dr. Aktivnost' marganecsoderzhashchej superoksiddismutazy pri rake molochnoj zhelezy. Sovremennye problemy nauki i obrazovaniya. 2024. № 2. S. 35–42. DOI: 10.17513/spno.33379 (in Russian).
9. Saptarova L.M., Imel'baeva E.A., Tuhbatova A.V. i dr. Soderzhanie citokinov v krovi u pacientok pri razlichnyh stadiyah raka molochnoj zhelezy. Kazanskij medicinskij zhurnal. 2022. T. 103. № 4. S. 947–954. DOI: 10.17816/KMJ70632 (in Russian).
10. Antyufeeva O.N., Budanova D.A., Il'gisonis I.S. i dr. Ocenka dinamiki pokazatelej okislitel'nogo stressa, rannih mar-kerov povrezhdeniya i disfunkcii miokarda u bol'nyh limfoproliferativnymi zabolevaniyami agressivnogo tipa na fone protivoopuholevoj terapii. Kardiologiya. 2020. T. 60. № 12. S. 76–82. DOI: 10.18087/cardio.2020.12.n1394 (in Russian).
11. Chalyj M.E., Ohobotov D.A., Afanas'evskaya E.V. i dr. Rol' tkanevogo rezonansnogo vzaimodejstviya v vyyavlenii onkologi-cheskih zabolevanij. Tekhnologii zhivyh sistem. 2022. T. 19. № 1. S. 5–13. DOI: 10.18127/j20700997-202201-01 (in Russian).
12. Chaikijurajai T., Tang W.H.W. Myeloperoxidase: a potential therapeutic target for coronary artery disease. Expert Opin. Ther. Targets. 2020. V. 24. № 7. P. 695–705. DOI: 10.1080/14728222.2020.1762177
13. Strzhepa A., Pritchard K.A., Dittel' B.N. Mieloperoksidaza: novyj igrok v autoimmunitete. Kletochnaya immunologiya. 2017. T. 317. S. 1–8. DOI: 10.1016/j.cellimm.2017.05.002 (in Russian).
14. Lanza F. Clinical manifestation of myeloperoxidase deficiency. J. Mol. Med. (Berl). 1998. V. 76(10). P. 676–681. DOI: 10.1007/s001090050267
15. Frangie C., Daher J. Role of myeloperoxidase in inflammation and atherosclerosis. Biomedical Reports. 2022. V. 16. Is. 53. P. 1–12. DOI: 10.3892/br.2022.1536
16. Blinova E.A., Korechenkova A.V., YAnishevskaya M.A., Akleev A.V. Vliyanie polimorfizma v genah antioksidantov na risk razvi-tiya zlokachestvennyh novoobrazovanij u obluchennyh lyudej. Medicina ekstremal'nyh situacij. 2024. T. 26. № 2. S. 49–55. DOI: 10.47183/mes.2024.022 (in Russian).
17. Grigor'eva D.V., Gorudko I.V, Kostevich V.A. i dr. Aktivnost' mieloperoksidazy v plazme krovi kak kriterij effektivno-sti lecheniya pacientov s serdechno-sosudistymi zabolevaniyami. Biomedicinskaya himiya. 2016. T. 62. № 3. S. 318–324. (in Russian).
18. Sokolov A.V., Kostevich V.A., Gorbunov N.P. i dr. Cvyaz' mezhdu aktivnoj mieloperoksidazoj i hlorirovannym ceruloplaz-minom v plazme krovi pacientov s serdechno-sosudistymi zabolevaniyami. Medicinskaya immunologiya. 2018. T. 20. № 5. S. 699–710. DOI: 10.15789/1563-0625-2018-5-699-710 (in Russian).
19. Bunenkova G.F., Salikova S.P., Grinevich V.B., Ivanyuk E.S. Rol' mieloperoksidazy v razvitii fibrillyacii predserdij i ishemicheskoj bolezni serdca. Klinicist. 2022. T. 16. № 3. S. 18–24. DOI: 10.17650/1818-8338-2022-16-3-K664 (in Russian).
20. Tingting Yan, Yunlong Pei, Hailong Yu et al. Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review. Heart Lung and Circulation. 2023. V. 33. Is. 5. P. 605–638. DOI: 10.1016/j.hlc.2023.12.006